ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0762

Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders

Christian Ammitzboell1, marianne Kragh thomsen2, Jakob Bøgn Andersen1, Jens Magnus Berth Jensen3, marie-Louise From Hermansen1, anders Dahl Johannsen1, Mads Lamm Larsen1, Clara Elbæl Mistegaard1, Susan Mikkelsen3, Fruzsina Szabados3, Signe Risbøl Vils1, Christian Erikstrup3, Ellen-Margrethe Hauge1 and Anne Troldborg1, 1Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 2Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, 3Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, Biologicals, COVID-19, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary outcome of this study was to investigate the percentage of RTX treated RD patients without detectable antibody responses after two vaccinations that mounted detectable antibody responses after a booster vaccination (3rd dose) or revaccination (3rd and 4th) vaccine dose. The secondary outcome was to examine if the level of B-cells in peripheral blood predicted the antibody response.

Methods: We included 91 RD patients, who had recieved RTX within the past 24 months and were vaccinated against COVID-19 with an mRNA vaccine. Patients were offered revaccination or a single booster vaccination with an mRNA vaccine. Serum total antibodies and specific IgG against SARS-CoV-2 spike protein were measured before and six weeks after the last vaccine dose. B-cells (CD19+CD45+) were measured by flow cytometry at inclusion. Logistic regression analyses were performed with the presence of SARS-CoV-2 antibodies after vaccination as the dependent variable.

The study was supported by an urestricted grant from the The Danish Rheumatism Association.

Results: Patient characteristics are given in Table 1. Most participants were female (69%) with a median age of 61 years, and the most common diagnosis were vasculitis (45%), rheumatoid arthritis (19%) and myositis (19%). 

Sixty-nine patients had undetectable anti-SARS-CoV-2 antibody levels after the initial vaccination. In these patients, 5 out 13 (38%) who recieved a booster dose and 18/56 (32%) who recieved a revaccination seroconverted, Figure 1A. This difference was not significant (p=0.67). Patients receiving re-vaccination had significantly higher antibody levels than patients receiving a booster dose (p< 0.001), Figure 1A.

Nearly all patients (7/8, 87.5 %), who had quantifiable B-lymphocytes but were seronegative before re-vaccination or boosting achieved detectable SARS-CoV-2 antibodies after six weeks (Fig. 1b). In contrast, 16 out of 58 patients (27.6%) with unquantifiable B-lymphocytes and unmeasurable antibodies before vaccination developed antibodies 6 weeks after booster/revaccination. 

In both univariate and multivariate logistic regression analysis, only B-cells higher than 10/µL before boost or revaccination were associated with seroconversion (p=0.009 and p=0.01, respectively), Table 2. Seroconversion was independent of age, gender, diagnosis, cumulative RTX dose, RTX treatment time, and time since last RTX treatment.

Conclusion: Continuously impaired humoral response to mRNA vaccines was found in most RTX treated RD patients after a booster dose (one-dose) or revaccination (two-doses). Re-vaccination lead to significantly higher antibody levels in patients who did not have a detecable humoral responce after the first two vaccine doses, compared to a booster dose. CD19+ B-cells are a significant predictor of humoral responce to vaccination. However, more than half of the patients with no measureable B-cells pre-vaccination developed a detecable humoral responce after revaccination.

Supporting image 1

Table 1. Patients Characteristics

Supporting image 2

Figure 1. Seroconversion after boost or revaccination.

Supporting image 3

Table 2. Univariate and multivariate logistic analysis with seroconversion as dependent variable


Disclosures: C. Ammitzboell, None; m. thomsen, None; J. Andersen, None; J. Jensen, None; m. Hermansen, None; a. Johannsen, None; M. Larsen, None; C. Mistegaard, None; S. Mikkelsen, None; F. Szabados, None; S. Vils, None; C. Erikstrup, None; E. Hauge, None; A. Troldborg, None.

To cite this abstract in AMA style:

Ammitzboell C, thomsen m, Andersen J, Jensen J, Hermansen m, Johannsen a, Larsen M, Mistegaard C, Mikkelsen S, Szabados F, Vils S, Erikstrup C, Hauge E, Troldborg A. Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rituximab-treated-rheumatic-patients-b-cell-levels-predict-sero-conversion-after-covid-19-boost-or-re-vaccination-in-initial-vaccine-non-responders/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-treated-rheumatic-patients-b-cell-levels-predict-sero-conversion-after-covid-19-boost-or-re-vaccination-in-initial-vaccine-non-responders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology